ProQR Therapeutics (NASDAQ:PRQR) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report released on Thursday,Benzinga reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Oppenheimer began coverage on ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price target for the company. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $6.80.

ProQR Therapeutics Stock Up 8.2%

ProQR Therapeutics stock opened at $1.98 on Thursday. The business has a 50 day moving average price of $1.60 and a two-hundred day moving average price of $1.99. The stock has a market cap of $208.61 million, a price-to-earnings ratio of -4.30 and a beta of 0.10. ProQR Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $5.53 million during the quarter, compared to analyst estimates of $6.12 million. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. On average, analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter worth about $51,000. XTX Topco Ltd lifted its position in ProQR Therapeutics by 1,057.4% during the 4th quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 107,713 shares in the last quarter. Ikarian Capital LLC lifted its position in ProQR Therapeutics by 67.2% during the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 600,000 shares in the last quarter. Quadrature Capital Ltd lifted its position in ProQR Therapeutics by 188.4% during the 4th quarter. Quadrature Capital Ltd now owns 104,231 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 68,091 shares in the last quarter. Finally, Millennium Management LLC lifted its position in ProQR Therapeutics by 80.8% during the 4th quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 194,369 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.